| Literature DB >> 25701870 |
Iltaf Ahmed1, Rebecca Buchert2, Mi Zhou3, Xinfu Jiao3, Kirti Mittal4, Taimoor I Sheikh4, Ute Scheller2, Nasim Vasli4, Muhammad Arshad Rafiq4, M Qasim Brohi5, Anna Mikhailov4, Muhammad Ayaz6, Attya Bhatti7, Heinrich Sticht8, Tanveer Nasr9, Melissa T Carter10, Steffen Uebe2, André Reis2, Muhammad Ayub11, Peter John7, Megerditch Kiledjian12, John B Vincent13, Rami Abou Jamra14.
Abstract
There are two known mRNA degradation pathways, 3' to 5' and 5' to 3'. We identified likely pathogenic variants in two genes involved in these two pathways in individuals with intellectual disability. In a large family with multiple branches, we identified biallelic variants in DCPS in three affected individuals; a splice site variant (c.636+1G>A) that results in an in-frame insertion of 45 nucleotides and a missense variant (c.947C>T; p.Thr316Met). DCPS decaps the cap structure generated by 3' to 5' exonucleolytic degradation of mRNA. In vitro decapping assays showed an ablation of decapping function for both variants in DCPS. In another family, we identified a homozygous mutation (c.161T>C; p.Phe54Ser) in EDC3 in two affected children. EDC3 stimulates DCP2, which decaps mRNAs at the beginning of the 5' to 3' degradation pathway. In vitro decapping assays showed that altered EDC3 is unable to enhance DCP2 decapping at low concentrations and even inhibits DCP2 decapping at high concentration. We show that individuals with biallelic mutations in these genes of seemingly central functions are viable and that these possibly lead to impairment of neurological functions linking mRNA decapping to normal cognition. Our results further affirm an emerging theme linking aberrant mRNA metabolism to neurological defects.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25701870 PMCID: PMC4424955 DOI: 10.1093/hmg/ddv069
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150